Heart failure & cardiomyopathiesCohort study
Time-Varying Analyses of Survival and Outcomes in Patients with HeartMate 3 Left Ventricular Assist Devices
- Retrospective cohort study
- single-centre
Authors' conclusion
Long-term survival on HeartMate 3 support was favourable in a large single-centre cohort.
Study context
- Population
- Patients with HeartMate 3 LV assist devices implanted at Cleveland Clinic, October 2015 to January 2023devices implanted
- Participants
- 431 patients
- Outcome
- Survival and time-varying risks of death, neurological events, gastrointestinal bleeding, device-related infections and other adverse events (multiphase hazard modelling)
- Follow-up
- 5 years post-implant
Main finding
As reported in the abstract
Survival · 1 and 5 years
| Group | Survival at 1 year | Survival at 5 years |
|---|---|---|
| HeartMate 3 | 88% | 58% |
Observational data: associations, not effects.
Safety
Neurological events (cumulative number/patient) · 1 and 5 years
- Cumulative neurological events/patient at 1 year
- 0.13
- Cumulative neurological events/patient at 5 years
- 0.29
- Risk highest within first postoperative week, then rapidly declined by 1 month
GI bleeding (cumulative number of events/patient) · 1 and 5 years
- Cumulative GI bleeding events/patient at 1 year
- 0.32
- Cumulative GI bleeding events/patient at 5 years
- 0.78
- Risk highest within 1 week postoperatively, gradually declined to a constant risk over the first year
Device-related infection · 1 and 5 years
- Patients with device-related infection
- 136
- Freedom from device-related infection at 1 year
- 77%
- Freedom from device-related infection at 5 years
- 45%
- Risk initially low, peaked at 6 months postoperatively, then gradually declined to a steady hazard
Original publication
Time-Varying Analyses of Survival and Outcomes in Patients with HeartMate 3 Left Ventricular Assist Devices. Eur J Heart Fail. Published 9 January 2025. doi:10.1002/ejhf.3577
Summarised from the published abstract; every number is checked against it